Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

MAtrix Therapy for Hard-to-heal ChrOnic Wounds

NCT: NCT05170984 · COMPLETED

NCT IDNCT05170984
StatusCOMPLETED
Start Date2022-02-10
Completion2024-12-30

Brief Summary

CACIPLIQ20® is currently a class III CE marked medical device available in various European and non-European countries, and currently primarily used in managing hard-to-heal wounds. This study is a prospective and standardized recording of patients' data followed in real-life conditions to appreciate the benefits of a therapeutic strategy including CACIPLIQ20® use. It also aims at collecting data to follow-up the device's efficacy and safety and estimate its cost-effectiveness.

Frequently Asked Questions

What is MAtrix Therapy for Hard-to-heal ChrOnic Wounds?

MAtrix Therapy for Hard-to-heal ChrOnic Wounds is a clinical trial registered under NCT05170984. Current status: COMPLETED.

What is the status of NCT05170984?

The current status of NCT05170984 (MAtrix Therapy for Hard-to-heal ChrOnic Wounds) is: COMPLETED.

When did MAtrix Therapy for Hard-to-heal ChrOnic Wounds start?

MAtrix Therapy for Hard-to-heal ChrOnic Wounds started on 2022-02-10.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.